Sodium Stibogluconate is pentavalent antimony (Sb) in differential complex formation with gluconic acid with leishmanicidal and potential antineoplastic activities. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phosphorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis. It is grouped under the following drug class(es): Leishmaniasis agents. Its therapeutic use is listed as anti-infectives, antiparasitics and antiprotozoals. The directory classifies it as a commercial API with a mineral/inorganic source/manufacturing origin. Other names for this substance include Stibanose, Stibinol and Stibogluconate de sodium. Its PubChem SID is 505883813.
Sodium stibogluconate
| CAS No | 16037-91-5 |
|---|---|
| Molecular Formula | N/A |
| Molecular Weight | 910.9 g/mol |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Sodium Stibogluconate is pentavalent antimony (Sb) in differential complex formation with gluconic acid with leishmanicidal and potential antineoplastic activities.
The listed CAS number is 16037-91-5.
The listed molecular formula is N/A.
The listed molecular weight is 910.9 g/mol.
N/A.
The source lists Stibanose, Stibinol and Stibogluconate de sodium.